Close Menu

NEW YORK (GenomeWeb) — Yikon Genomics said today that it has signed an agreement to launch its noninvasive chromosomal screening assay for aneuploidy with the Center for Reproductive Health & Gynecology (CRHG), a Beverly Hills, California-based in vitro fertilization center.

The test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation, according to Shanghai-based Yikon. It analyzes in vitro embryo culture medium and does not require a biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.